Literature DB >> 19225112

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.

Surojit Sur1, Raymond Pagliarini, Fred Bunz, Carlo Rago, Luis A Diaz, Kenneth W Kinzler, Bert Vogelstein, Nickolas Papadopoulos.   

Abstract

Through targeted homologous recombination, we developed a panel of matched colorectal cancer cell lines that differ only with respect to their endogenous TP53 status. We then used these lines to define the genes whose expression was altered after DNA damage induced by ionizing radiation. Transcriptome analyses revealed a consistent up-regulation of polo-like kinase 1 (PLK1) as well as other genes controlling the G(2)/M transition in the cells whose TP53 genes were inactivated compared with those with WT TP53 genes. This led to the hypothesis that the viability of stressed cells without WT TP53 depended on PLK1. This hypothesis was validated by demonstrating that stressed cancer cells without WT TP53 alleles were highly sensitive to PLK1 inhibitors, both in vivo and in vitro.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19225112      PMCID: PMC2656188          DOI: 10.1073/pnas.0813333106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  60 in total

Review 1.  p53 and human cancer: the first ten thousand mutations.

Authors:  P Hainaut; M Hollstein
Journal:  Adv Cancer Res       Date:  2000       Impact factor: 6.242

2.  Dose-dependent effects of DNA-damaging agents on p53-mediated cell cycle arrest.

Authors:  D Chang; F Chen; F Zhang; B C McKay; M Ljungman
Journal:  Cell Growth Differ       Date:  1999-03

3.  Surfing the p53 network.

Authors:  B Vogelstein; D Lane; A J Levine
Journal:  Nature       Date:  2000-11-16       Impact factor: 49.962

Review 4.  Cellular senescence as a tumor-protection mechanism: the essential role of counting.

Authors:  W E Wright; J W Shay
Journal:  Curr Opin Genet Dev       Date:  2001-02       Impact factor: 5.578

5.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage.

Authors:  F Bunz; A Dutriaux; C Lengauer; T Waldman; S Zhou; J P Brown; J M Sedivy; K W Kinzler; B Vogelstein
Journal:  Science       Date:  1998-11-20       Impact factor: 47.728

6.  High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide.

Authors:  M Roberge; R G Berlinck; L Xu; H J Anderson; L Y Lim; D Curman; C M Stringer; S H Friend; P Davies; I Vincent; S J Haggarty; M T Kelly; R Britton; E Piers; R J Andersen
Journal:  Cancer Res       Date:  1998-12-15       Impact factor: 12.701

Review 7.  p53, the cellular gatekeeper for growth and division.

Authors:  A J Levine
Journal:  Cell       Date:  1997-02-07       Impact factor: 41.582

Review 8.  The p53 pathway.

Authors:  C Prives; P A Hall
Journal:  J Pathol       Date:  1999-01       Impact factor: 7.996

Review 9.  Regulation of p53 downstream genes.

Authors:  W S el-Deiry
Journal:  Semin Cancer Biol       Date:  1998       Impact factor: 15.707

Review 10.  The MDM2 gene amplification database.

Authors:  J Momand; D Jung; S Wilczynski; J Niland
Journal:  Nucleic Acids Res       Date:  1998-08-01       Impact factor: 16.971

View more
  156 in total

1.  The microtubule cytoskeleton is required for a G2 cell cycle delay in cancer cells lacking stathmin and p53.

Authors:  Bruce K Carney; Victoria Caruso Silva; Lynne Cassimeris
Journal:  Cytoskeleton (Hoboken)       Date:  2012-03-29

2.  Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.

Authors:  Yongzhen Qian; Emily Hua; Kheem Bisht; Stephan Woditschka; Konstantine W Skordos; David J Liewehr; Seth M Steinberg; Edi Brogi; Muzaffar M Akram; J Keith Killian; Daniel C Edelman; Marbin Pineda; Stephanie Scurci; Yan Y Degenhardt; Sylvie Laquerre; Thomas A Lampkin; Paul S Meltzer; Kevin Camphausen; Patricia S Steeg; Diane Palmieri
Journal:  Clin Exp Metastasis       Date:  2011-09-21       Impact factor: 5.150

Review 3.  Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy.

Authors:  Kyung S Lee; Terrence R Burke; Jung-Eun Park; Jeong K Bang; Eunhye Lee
Journal:  Trends Pharmacol Sci       Date:  2015-10-17       Impact factor: 14.819

Review 4.  Tissue Engineering and Regenerative Medicine 2015: A Year in Review.

Authors:  Holly Wobma; Gordana Vunjak-Novakovic
Journal:  Tissue Eng Part B Rev       Date:  2016-02-23       Impact factor: 6.389

5.  Efficient introduction of specific TP53 mutations into mouse embryonic fibroblasts and embryonic stem cells.

Authors:  Quan-Xiang Wei; Franciscus van der Hoeven; Monica Hollstein; Adam F Odell
Journal:  Nat Protoc       Date:  2012-05-17       Impact factor: 13.491

6.  DZNep represses Bcl-2 expression and modulates apoptosis sensitivity in response to Nutlin-3a.

Authors:  Yalu Zhou; Ricardo E Perez; Lei Duan; Carl G Maki
Journal:  Cancer Biol Ther       Date:  2018-03-13       Impact factor: 4.742

7.  RNAi screen identifies a synthetic lethal interaction between PIM1 overexpression and PLK1 inhibition.

Authors:  Riet van der Meer; Ha Yong Song; Seong-Hoon Park; Sarki A Abdulkadir; Meejeon Roh
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

Review 8.  Development of Preclinical Models to Understand and Treat Colorectal Cancer.

Authors:  Judith S Sebolt-Leopold
Journal:  Clin Colon Rectal Surg       Date:  2018-04-01

9.  IL-1Ra protects hematopoietic cells from chemotoxicity through p53-induced quiescence.

Authors:  Hao Ye; Lan Qian; Shunying Zhu; Shaorong Deng; Xia Wang; Jiang Zhu; Gerald L Chan; Yan Yu; Wei Han
Journal:  FASEB J       Date:  2019-08-05       Impact factor: 5.191

10.  Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype.

Authors:  Campbell McInnes; Kara Estes; Merissa Baxter; Zhengguan Yang; Doaa Boshra Farag; Paul Johnston; John S Lazo; Jianjun Wang; Michael D Wyatt
Journal:  Mol Cancer Ther       Date:  2012-07-30       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.